Novo Nordisk warns 2026 sales and profit fall amid GLP‑1 price cuts, rising competition

Novo Nordisk signals tougher 2026 as pricing and competition reshape GLP‑1 market

Novo Nordisk is warning of a sharper-than-expected pullback in sales and operating profit for 2026 as shifts in U.S. pricing and growing competition squeeze near‑term margins. The Danish drugmaker pre‑releases guidance saying it now expects sales and operating profit to fall between 5% and 13% at constant exchange rates, citing significantly lower U.S. prices for its top-selling weight‑loss drug Wegovy and the impact of lower‑cost semaglutide copies. CEO Mike Doustdar tells media that "people should expect that it goes down before it comes back up," framing the move as a short‑term tradeoff to improve affordability for patients.

Market and competitor dynamics are intensifying in the GLP‑1 sector, with Eli Lilly’s Zepbound capturing U.S. share and compounding pharmacies and other knockoffs eroding price discipline. Novo highlights a stronger-than-expected launch of a Wegovy pill in the U.S. — drawing roughly 170,000 users in four weeks and delivering about 16.6% efficacy in early measures — but says the positive uptake does not fully offset price declines on its existing injectables business. Analysts debate whether the company’s pre‑announcement is a conservative "kitchen sink" that management hopes to beat, or a realistic reset given accelerating genericisation and regional patent expiries.

The guidance underscores a broader industry transition as GLP‑1 therapies move from exclusivity into a more competitive, price‑sensitive phase. Novo notes the end of exclusivity for Wegovy and Ozempic in markets including China, Brazil and Canada, and points to margin pressure from pharmacy compounding and other lower‑priced entrants. Company messaging balances the immediate commercial pain with longer‑term optimism about widespread GLP‑1 adoption and the strategic importance of diversified formulations and access initiatives.

Wegovy pill momentum provides partial commercial cushion

Novo’s pill launch gains serve as a strategic hedge, with early uptake suggesting demand for oral GLP‑1 options. Management stresses the pill supports broader access and could drive long‑term market expansion, even as near‑term price effects dampen revenue.

Public outreach via cycling sponsorship remains central to brand and health messaging

Team Novo Nordisk’s wildcard entry to Milan‑Sanremo reinforces the company’s public‑health positioning, using high‑profile sport to promote diabetes management and destigmatise treatment — a visibility play that complements its commercial and access objectives.